US Breast Cancer Drug Market Outlook 2022 Report

“US Breast Cancer Drug Market Outlook 2022” Report Highlights:

* US Breast Cancer Tendencies
* US Breast Cancer Drug Market Outline
* US Breast Cancer Drug Market Dynamics
* Breast Cancer Risk Undercurrents
* US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
* US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs

Download Report Sample Weblink:

https://www.kuickresearch.com/report-US-Breast-Cancer-Drug-Market-Outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. US Cancer Prevalence Rate

1.1 Overview

1.2 Glimpse of Past Cancer Incidences

1.3 Current Drifts in Cancer Frequencies

1.4 Estimated Future Cancer Occurrences



2. US Breast Cancer Tendencies

2.1 Indication

2.2 Breast Cancer Historical Incidences

2.3 Recent inclinations in Breast Cancer

2.4 Breast Cancer Frequencies over Age & Race



3. Breast Cancer Risk Undercurrents

3.1 Hormonal Aspects

3.2 Family History & Genetic Predisposition

3.3 Cumulative Age & Elevated Risk

3.4 Management of Breast Cancer



4. US Breast Cancer Drug Market Outline

4.1 Topographical Arcade Sales

4.2 HER-2 Positive Drug Market



5. US Breast Cancer Drug Market Dynamics

5.1 Breast Cancer Market Accelerative Parameters

5.2 Breast Cancer Market Challenges



6. US Breast Cancer Drug Market Future Aspects



US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis



7. Eribulin (Halaven)

7.1 Clinical Introduction

7.2 Brand Names

7.3 Recording & Reporting Of Clinical Adverse Events



8. Trastuzumab Emtansine (Kadcyla)

8.1 Clinical Introduction

8.2 Brand Names

8.3 Recording & Reporting Of Clinical Adverse Events



9. Palbociclib (Ibrance)

9.1 Clinical Introduction

9.2 Brand Names

9.3 Recording & Reporting Of Clinical Adverse Events



10. Pertuzumab (Omnitarg & Perjeta)

10.1 Clinical Introduction

10.2 Brand Names

10.3 Recording & Reporting Of Clinical Adverse Events



11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)

11.1 Clinical Introduction

11.2 Brand Names

11.3 Recording & Reporting Of Clinical Adverse Events



12. Lapatinib (Tykerb)

12.1 Clinical Introduction

12.2 Brand Names

12.3 Recording & Reporting Of Clinical Adverse Events



13. Tamoxifen Oral Liquid (Soltamox)

13.1 Clinical Introduction

13.2 Brand Names

13.3 Recording & Reporting Of Clinical Adverse Events



14. Fulvestrant (Faslodex)

14.1 Clinical Introduction

14.2 Brand Names

14.3 Recording & Reporting Of Clinical Adverse Events



15. Anastrozole (Arimidex)

15.1 Clinical Introduction

15.2 Brand Names

15.3 Recording & Reporting Of Clinical Adverse Events



16. Ixabepilone (Ixempra)

16.1 Clinical Introduction

16.2 Brand Names

16.3 Recording & Reporting Of Clinical Adverse Events



17. Toremifene (Fareston)

17.1 Clinical Introduction

17.2 Brand Names

17.3 Recording & Reporting Of Clinical Adverse Events



18. Letrozole (Femara)

18.1 Clinical Introduction

18.2 Brand Names

18.3 Recording & Reporting Of Clinical Adverse Events



19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))

19.1 Clinical Introduction

19.2 Brand Names



20. Exemestane (Aromasin)

20.1 Clinical Introduction

20.2 Brand Names

20.3 Recording & Reporting Of Clinical Adverse Events



21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)

21.1 Clinical Introduction

21.2 Brand Names



22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)

22.1 Clinical Introduction

22.2 Brand Names



23. Fluoxymesterone

23.1 Clinical Introduction

23.2 Recording & Reporting Of Clinical Adverse Events



24. Competitive Landscape

24.1 Agilent Technologies

24.2 AstraZeneca

24.3 Bayer HealthCare Pharmaceuticals

24.4 Bristol-Myers Squibb

24.5 Eisai Co Ltd

24.6 Eli Lilly

24.7 Novartis

24.8 Onyx Pharmaceuticals

24.9 Orion

24.10 Perrigo

24.11 Pfizer

24.12 Roche

Figure 1-1: Top Ten Countries in Cancer Incidence Trends

Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012

Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016

Figure 2-1: Relationship between Age & Breast Cancer

Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity

Figure 3-1: Various Risk Factors Associated With Breast Cancer

Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016

Figure 4-2: HER-2 Positive Receptor & Herceptin

Figure 5-1: Accelerative Parameters of Breast Cancer Market

Figure 5-2: Current Challenges in Breast Cancer Therapeutics

Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022

Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022

Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022

Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022

Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022

Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022

Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022

Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022

Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022

Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022

Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022

Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022

Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022

Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022

Figure 18-1: Femara - US Sales (Million US$), 2015-2022

Figure 18-2: Femara - Global Sales (Million US$), 2015-2022

Figure 24-1: Novartis - Clinical Pipeline

Figure 24-2: Roche - Clinical Pipeline



Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016

Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016

Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.